CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $4.2B, above the global median of $1.18B
- PositionCurrent ratio is 50.82×, higher than 95% of its Biotechnology peers (median 5.28×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.20BUSDvs all stocks (USD)
Revenue (TTM)
53.81MUSDvs all stocks (USD)
Profit Margin
-229.92%vs Biotechnology peers
Beta
1.12xvs all stocks
52-Week Change
189.81%vs all stocks
Market Capitalization
4.20BUSDvs all stocks (USD)
Enterprise Value
3.22BUSDvs all stocks (USD)
Forward P/E
-14.79xvs Biotechnology peers
Price to Sales (TTM)
78.08xvs Biotechnology peers
Price to Book (MRQ)
9.18xvs Biotechnology peers
Enterprise to Revenue
59.84xvs Biotechnology peers
Enterprise to EBITDA
-23.95xvs Biotechnology peers
Profit Margin
-229.92%vs Biotechnology peers
Operating Margin
-253.38%vs Biotechnology peers
Return on Assets (TTM)
-12.99%vs Biotechnology peers
Return on Equity (TTM)
-21.34%vs Biotechnology peers
Revenue (TTM)
53.81MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.3980USDUpdated Sep 28, 2026Gross Profit (TTM)
-79.84MUSDvs all stocks (USD)
EBITDA (TTM)
-134.42MUSDvs all stocks (USD)
Net Income (TTM)
-123.72MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-100.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-143.90MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-71.87MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
62.38MUSDFY2025 · Dec 31, 2025Operating Income
-111.29MUSDvs all stocks (USD)
Pre-tax Income
-101.59MUSDFY2025 · Dec 31, 2025Income Tax Expense
4.00KUSDFY2025 · Dec 31, 2025Net Income
-101.59MUSDFY2025 · Dec 31, 2025EBIT
-111.29MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-109.01MUSDFY2025 · Dec 31, 2025Research & Development
132.16MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
41.51MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.63MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-101.59MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-135.54MUSDFY2025 · Dec 31, 2025Free Cash Flow
-136.59MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
114.85MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-101.59MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.28MUSDFY2025 · Dec 31, 2025Stock-based Compensation
26.43MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.88MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-825.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-65.72MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.05MUSDFY2025 · Dec 31, 2025Purchase of Investments
-264.46MUSDFY2025 · Dec 31, 2025Sale of Investments
224.64MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-40.87MUSDFY2025 · Dec 31, 2025Other Financing Charges
-36.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
212.36MUSDFY2025 · Dec 31, 2025Shares Outstanding
168.38MSharesUpdated Sep 28, 2026Float Shares
120.34MSharesUpdated Sep 28, 2026Shares Short
41.87MSharesUpdated Sep 28, 2026Short Ratio
18.63daysvs all stocks
Short % of Shares Outstanding
25.11%vs all stocks
% Held by Insiders
1.17%vs all stocks
% Held by Institutions
128.45%vs all stocks
Total Cash (MRQ)
1.01BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.01USDUpdated Sep 28, 2026Total Debt (MRQ)
31.99MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0312xvs Biotechnology peers
Current Ratio (MRQ)
50.82xvs Biotechnology peers
Book Value per Share (MRQ)
2.72USDUpdated Sep 28, 2026Total Assets
398.69MUSDvs all stocks (USD)
Total Current Assets
353.76MUSDFY2025 · Dec 31, 2025Total Liabilities
52.51MUSDFY2025 · Dec 31, 2025Total Non-current Assets
44.93MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
30.83MUSDFY2025 · Dec 31, 2025Total Current Liabilities
21.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
112.28MUSDFY2025 · Dec 31, 2025Other Short-term Investments
230.86MUSDFY2025 · Dec 31, 2025Accounts Payable
1.18MUSDFY2025 · Dec 31, 2025Short-term Debt
2.74MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
1.29MUSDFY2025 · Dec 31, 2025Long-term Debt
30.83MUSDFY2025 · Dec 31, 2025Common Stock (Book)
136.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-603.15MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
346.18MUSDvs all stocks (USD)
52-Week Low
6.69USDUpdated Sep 28, 202652-Week High
34.39USDUpdated Sep 28, 202652-Week Change
189.81%vs all stocks
Beta
1.12xvs all stocks
50-Day MA
25.37USDUpdated Sep 28, 2026200-Day MA
20.50USDUpdated Sep 28, 2026Avg 10-Day Volume
3.46MSharesUpdated Sep 28, 2026Avg 30-Day Volume
2.65MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.8400USDUpdated Sep 28, 2026Other Income / Expense
4.07MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 50.82×, higher than 95% of its Biotechnology peers (median 5.28×)Significant
Current ratio: 50.82Industry median: 5.28Industry P95: 22.31Peers compared: 193
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $4.2B, above the global median of $1.18BNotable
Market cap (USD): 4,201,770,345Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
LivaNova PLC
Tier 1ProductionApproval-Gated PipelineRuleRisk
Indivior Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Xuanzhu Biopharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Medical System Holdings Limited
Tier 1ProductionApproval-Gated PipelineRule
Edgewise Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
AbCellera Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Viking Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Integer Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRule
Dong-E-E-JiaoCo Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Pulse Biosciences Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity Configuration
Relay Therapeutics Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity Configuration
Suzhou Novoprotein Scientific Co., Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityLow-Leverage Liquidity Configuration